Publications powered by Harvard Catalyst Profiles

1. Parent and Physician Understanding of Prognosis in Hospitalized Children With Advanced Heart Disease. J Am Heart Assoc. 2021 Jan 19; 10(2):e018488. View abstract
2. Value of Troponin Testing for Detection of Heart Disease in Previously Healthy Children. J Am Heart Assoc. 2020 02 18; 9(4):e012897. View abstract
3. Delayed Presentation of Traumatic Pericardial Rupture: Diagnostic and Surgical Considerations for Treatment. Heart Surg Forum. 2018 06 14; 21(4):E254-E256. View abstract
4. Staged ventricular recruitment in patients with borderline ventricles and large ventricular septal defects. J Thorac Cardiovasc Surg. 2018 07; 156(1):254-264. View abstract
5. Longitudinal Outcomes of Patients With Single Ventricle After the Fontan Procedure. J Am Coll Cardiol. 2017 Jun 06; 69(22):2735-2744. View abstract
6. Truncus arteriosus versus tetralogy of Fallot with pulmonary atresia. Cardiol Young. 2017 May; 27(4):801-803. View abstract
7. De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. Science. 2015 Dec 04; 350(6265):1262-6. View abstract
8. Survival data and predictors of functional outcome an average of 15?years after the Fontan procedure: the pediatric heart network Fontan cohort. Congenit Heart Dis. 2015 Jan-Feb; 10(1):E30-42. View abstract
9. Transient elastography may identify Fontan patients with unfavorable hemodynamics and advanced hepatic fibrosis. Congenit Heart Dis. 2014 Sep-Oct; 9(5):438-47. View abstract
10. Stented bovine jugular vein graft (Melody valve) for surgical mitral valve replacement in infants and children. J Thorac Cardiovasc Surg. 2014 Oct; 148(4):1443-9. View abstract
11. The relationship of patient medical and laboratory characteristics to changes in functional health status in children and adolescents after the Fontan procedure. Pediatr Cardiol. 2014 Apr; 35(4):632-40. View abstract
12. De novo mutations in histone-modifying genes in congenital heart disease. Nature. 2013 Jun 13; 498(7453):220-3. View abstract
13. Cardiac performance and quality of life in patients who have undergone the Fontan procedure with and without prior superior cavopulmonary connection. Cardiol Young. 2013 Jun; 23(3):335-43. View abstract
14. Outcome after repair of atrioventricular septal defect with tetralogy of Fallot. J Thorac Cardiovasc Surg. 2012 Feb; 143(2):338-43. View abstract
15. Late status of Fontan patients with persistent surgical fenestration. J Am Coll Cardiol. 2011 Jun 14; 57(24):2437-43. View abstract
16. Factors associated with serum brain natriuretic peptide levels after the Fontan procedure. Congenit Heart Dis. 2011 Jul-Aug; 6(4):313-21. View abstract
17. The Fontan patient: inconsistencies in medication therapy across seven pediatric heart network centers. Pediatr Cardiol. 2010 Nov; 31(8):1219-28. View abstract
18. Laboratory measures of exercise capacity and ventricular characteristics and function are weakly associated with functional health status after Fontan procedure. Circulation. 2010 Jan 05; 121(1):34-42. View abstract
19. De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. Nat Genet. 2009 Aug; 41(8):931-5. View abstract
20. Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study. J Am Coll Cardiol. 2008 Jul 08; 52(2):85-98. View abstract
21. Functional status, heart rate, and rhythm abnormalities in 521 Fontan patients 6 to 18 years of age. J Thorac Cardiovasc Surg. 2008 Jul; 136(1):100-7, 107.e1. View abstract
22. Genomics of congenital heart disease. Willard HF, Ginsburg GS, editors., Handbook of genomic medicine. 2008; In Press. View abstract
23. Functional state of patients with heterotaxy syndrome following the Fontan operation. Cardiol Young. 2007 Sep; 17 Suppl 2:44-53. View abstract
24. Etiology, management, and outcome of pediatric pericardial effusions. Pediatr Cardiol. 2008 Jan; 29(1):90-4. View abstract
25. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest. 2006 Aug; 116(8):2218-25. View abstract
26. Synthetic Oligonucleotide Multiplex Ligation-dependent Probe Amplification (MLPA) for the Detection of Novel Deletions in Candidate Genes Causing Tetralogy of Fallot. AHA. 2006; Submitted. View abstract
27. CARK, a novel cacardiac specific kinase, mediates structural remodeling and contractile function following myocardial infarction. AHA. 2006; submitted. View abstract
28. Pericardial Diseases. Keane JB, Lock, JE, Fyler DC, editors., Nadas’ Pediatric Cardiology. 2006; 459-466. View abstract
29. Tetralogy of Fallot. Keane JB, Lock, JE, Fyler DC, editors., Nadas’ Pediatric Cardiology. 2006; 559-579. View abstract
30. Sarcomeric genes involved in reverse remodeling of the heart during left ventricular assist device support. J Heart Lung Transplant. 2005 Jan; 24(1):73-80. View abstract
31. Right ventricular pseudoaneurysm after modified Norwood procedure. Ann Thorac Surg. 2004 Oct; 78(4):e72-3. View abstract
32. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol. 2003 Sep; 35(9):1043-53. View abstract
33. Array transcription profiling: molecular phenotyping of rodent cardiovascular models. Hoit BD, Walsh RA, editors. Cardiovascular physiology in the genetically engineered mouse. 2002; 53-61. View abstract
34. Atherosclerosis: a cancer of the blood vessels? Am J Clin Pathol. 2001 Dec; 116 Suppl:S97-107. View abstract
35. Atherosclerosis and cancer: common molecular pathways of disease development and progression. Ann N Y Acad Sci. 2001 Dec; 947:271-92; discussion 292-3. View abstract
36. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation. 2001 Oct 16; 104(16):1899-904. View abstract
37. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000 Sep 01; 87(5):E1-9. View abstract
38. Conservation of sequence and expression of Xenopus and zebrafish dHAND during cardiac, branchial arch and lateral mesoderm development. Mech Dev. 2000 Jul; 95(1-2):231-7. View abstract
39. Differential rescue of visceral and cardiac defects in Drosophila by vertebrate tinman-related genes. Proc Natl Acad Sci U S A. 1998 Aug 04; 95(16):9366-71. View abstract
40. Zebrafish: genetic and embryological methods in a transparent vertebrate embryo. Methods Cell Biol. 1997; 52:67-82. View abstract
41. A new tinman-related gene, nkx2.7, anticipates the expression of nkx2.5 and nkx2.3 in zebrafish heart and pharyngeal endoderm. Dev Biol. 1996 Dec 15; 180(2):722-31. View abstract
42. Three zebrafish MEF2 genes delineate somitic and cardiac muscle development in wild-type and mutant embryos. Mech Dev. 1996 Oct; 59(2):205-18. View abstract
43. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell. 1996 Feb 09; 84(3):491-5. View abstract
44. Recent advances in the Laboratory of Molecular and Cellular Cardiology. Ann Thorac Surg. 1995 Dec; 60(6 Suppl):S509-12. View abstract
45. A fourth human MEF2 transcription factor, hMEF2D, is an early marker of the myogenic lineage. Development. 1993 Aug; 118(4):1095-106. View abstract
46. MEF2C, a MADS/MEF2-family transcription factor expressed in a laminar distribution in cerebral cortex. Proc Natl Acad Sci U S A. 1993 Feb 15; 90(4):1546-50. View abstract
47. Human myocyte-specific enhancer factor 2 comprises a group of tissue-restricted MADS box transcription factors. Genes Dev. 1992 Sep; 6(9):1783-98. View abstract
48. Alternative splicing is an efficient mechanism for the generation of protein diversity: contractile protein genes as a model system. Adv Enzyme Regul. 1991; 31:261-86. View abstract
49. Tissue specific alternative splicing in the troponin T multigene family. Renkawitz R, editor. Tissue Specific Gene Expression. 1989; 199-215. View abstract
50. Alternative splicing of contractile protein minigene constructs is directed by cis and trans mechanisms. Mechanisms of control of gene expression. 1988; 67:265-77. View abstract
51. Developmentally induced, muscle-specific trans factors control the differential splicing of alternative and constitutive troponin T exons. Cell. 1987 Jun 19; 49(6):793-803. View abstract
52. Alternative splicing: a ubiquitous mechanism for the generation of multiple protein isoforms from single genes. Annu Rev Biochem. 1987; 56:467-95. View abstract
53. Promoter selection and alternative pre-mRNA splicing are used to generate complex contractile protein phenotypes. Norman AW, Vanaman TC, Means AR, editors. Calcium-binding Proteins in Health and Disease. 1987; 518-532. View abstract
54. Complete nucleotide sequence of the fast skeletal troponin T gene. Alternatively spliced exons exhibit unusual interspecies divergence. J Mol Biol. 1986 Apr 05; 188(3):313-24. View abstract
55. Alternative splicing: a common mechanism for the generation of contractile protein diversity from single genes. Molecular biology of muscle development. 1986; 29:387-410. View abstract
56. Intricate combinatorial patterns of exon splicing generate multiple regulated troponin T isoforms from a single gene. Cell. 1985 May; 41(1):67-82. View abstract
57. Conversion of thyroxine to triiodothyronine in the anterior pituitary gland and the influence of this process on thyroid status. Horm Metab Res Suppl. 1984; 14:79-85. View abstract
58. Comparison of thyroxine and 3,3',5'-triiodothyronine metabolism in rat kidney and liver homogenates. Metabolism. 1979 Nov; 28(11):1139-46. View abstract